Each capsule contains: Colchicine.....0.6 ma USUAL ADULT DOSAGE: See accompanving prescribing information. Store at 20° to 25°C (68° to 77°F). [See LISP Controlled Boom Temperature1 PROTECT FROM LIGHT AND MOISTURE Keep container tightly closed. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN. Distr by West-Ward Pharmaceuticals Corp. Fatontown NJ 07724



c50000074/01

Each capsule contains: Colchicine.....0.6 mg USUAL ADULT DOSAGE: See accompanying prescribing information. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Boom Temperature1, PROTECT FROM LIGHT AND MOISTURE. Keep container tightly closed. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure

KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN. Distr by West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724



4 ω I ω -8 Т 4 c50000038/01

W Z

NDC 0143-3018-10

Colchicine Capsules

0.6 mg

Pharmacist: Dispense the enclosed Medication Guide to each patient.

1,000 CAPSULES Bg Only



Each capsule contains: Colchicine 0.6 mg


USUAL ADULT DOSAGE: See accompanying prescribing information.

Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. PROTECT FROM LIGHT AND MOISTURE. Keep container tightly closed.

Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.

KEEP THIS AND ALL MEDICATION OUT OF THE REACH OF CHILDREN.

Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724



Each capsule contains: Colchicine....... 0.6 mg USUAL ADULT DOSAGE: See accompanying prescribing information Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. PROTECT FROM LIGHT AND MOISTURE Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep tightly closed. KEEP OUT OF THE REACH OF CHILDREN Hikma Americas Inc Memphis, TN 38120 Mfd by West Ward Columbus Inc. Columbus, OH 43228



050000182/01

Each capsule contains: Colchicine..... 0.6 mg USUAL ADULT DOSAGE: See accompanying prescribing information. Store at 20° to 25°C (68° to 77°F). ISee USP Controlled Room Temperaturel, PROTECT FROM LIGHT AND MOISTURE. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep tightly closed. KEEP OUT OF THE REACH OF CHILDREN. Hikma Americas Inc Memph s TN 38120 West Ward Columbus Inc Columbus OH 43228



Each cansule contains: Colchicine..... 0.6 ma USUAL ADULT DOSAGE: See accompanying prescribing information. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Boom peraturel. PROTECT FROM LIGHT AND MOISTURE Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure. Keep tightly closed. KEEP OUT OF THE REACH OF CHILDREN. Mfd for Hikma Americas Inc Memphis.TN 38120 Mfd by West Ward Columbus Inc. Columbus, OH 43228





NDC 59467-318-10

MITIGARE[®] (colchicine) Capsules

0.6 mg

Rx Only Pharmacist: Dispense the enclosed Medication Guide to each patient.

1,000 CAPSULES



KEEP OUT OF THE REACH OF CHILDREN.

Mfd. for: Hikma Americas Inc. Memphis,TN 38120

Mfd. by: West-Ward Columbus Inc. Columbus, OH 43228



HIGHLIGHTS OF PRESCRIBING INFORMATION Rx Only These highlights do not include all the information needed to use COLCHICINE CAPSULES safely and effectively. See full pre- scribing information for COLCHICINE CAPSULES. COLCHICINE capsules, for oral use Initial U.S. Approval: 1961	 Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death (5.3, 7). Neuromuscular toxicity: Myotoxicity including rhabdomyolysis may occur, especially in combination with other drugs known to cause this effect. Consider temporary interruption or discontinuation of colchicine capsules (5.4, 7). 	1
INDICATIONS AND USAGE Oclohicine capsules are indicated for prophylaxis of gout flares in adults (1).	ADVERSE REACTIONS	1
Limitations of use:	To report SUSPECTED ADVERSE REACTIONS, contact West-Ward Pharmaceuticals Corp. at 1-800-962-8364 or FDA at 1-800-	i
The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied.	FDA-1088 or www.fda.gov/medwatch.	What is
Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes.	DRUG INTERACTIONS Co-administration of P-gp or CYP3A4 inhibitors or inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin or cyclosporine) have	i capsule
DOSAGE AND ADMINISTRATION O.6 mg (one capsule) once or twice daily (2). Maximum dose 1.2 mg/day.	been reported to lead to colchicine toxicity. The potential for drug-drug interactions must be considered prior to and during therapy.	Colchic
Colchicine capsules are administered orally, without regard to meals (2).	Concomitant use of colchicine capsules and inhibitors of CYP3A4 or P-gp should be avoided if possible. If co-administration of	chicine
DOSAGE FORMS AND STRENGTHS	colchicine capsules and an inhibitor of CYP3A4 or P-gp is necessary, the dose of colchicine capsules should be reduced and the patient should be monitored carefully for colchicine toxicity (7, 12.3).	! • Takin
• 0.6 mg Capsules (3).	USE IN SPECIFIC POPULATIONS	colch
CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules in conjunction with drugs that inhibit both P-gp	 In the presence of renal or hepatic impairment, patients should be monitored closely and dose adjustment should be considered as necessary (8.6, 8.7). 	• Tell y
and CYP3A4 (4).	 Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (8.1). 	if you
 Patients with both renal and hepatic impairment should not be given colchicine capsules (4). 	 Nursing Mothers: Caution should be exercised when administered to a nursing woman (8.3). Geriatric Use: The recommended dose of colchicine should be based on renal/hepatic function (8.5). 	may
Fatal overdoses have been reported with colchicine in adults and children. Keep colchicine capsules out of the reach of children	See 17 for PATIENT COUNSELING INFORMATION and Medication Guide	• Even
 Blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic anemia have been reported 	Revised: 02/2018	
(5.2).		i or de
FULL PRESCRIBING INFORMATION: CONTENTS*	8.4 Pediatric Use 8.5 Geriatric Use	¦ What a
1 INDICATIONS AND USAGE 2 Dosage and Administration	8.6 Renal Impairment	! Colchic
2.1 Gout Prophylaxis	8.7 Hepatic Impairment 9 DRUG ABUSE AND DEPENDENCE	flares ir
3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS	10 OVERDOSAGE 11 DESCRIPTION	! It is no
5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose	12 CLINICAL PHARMACOLOGY	i ment o
5.2 Blood Dyscrasias	12.1 Mechanism of Action 12.3 Pharmacokinetics	1
5.3 Interactions with CYP3A4 and P-gp Inhibitors5.4 Neuromuscular Toxicity	13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility	• acute
6 ADVERSE REACTIONS 7 DRUG INTERACTIONS	14 CLINICAL STUDIES	Colchic
7.1 CYP3A4	16 HOW SUPPLIED/STORAGE AND HANDLING 16.1 How Supplied	treat pa
7.2 P-glycoprotein 7.3 HMG-CoA Reductase Inhibitors and Fibrates	16.2 Storage 17 PATIENT COUNSELING INFORMATION	tions.
7.4 Drug-Drug Interaction Studies		
	MEDICATION GUIDE	lt is not
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy	PACKAGE LABEL PRINCIPAL DISPLAY	1
8 USE IN SPECIFIC POPULATIONS		Who sh
USE IN SPECIFIC POPULATIONS S.1 Use in Pregnancy Labor and Delivery Use in Nursing Mothers	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed.	Who sh
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION	PACKAGE LABEL PRINCIPAL DISPLAY	Who sh Do not you tak
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-	Who sh Do not you tak have b
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION I INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults.	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low- ering the dose of colchicine:	Who sh Do not you tak have b "What
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting	Who sh Do not you tal have b "What capsule
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy	Who sh Do not you tak have b "What capsule What s
B USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION I INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied.	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low- ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash	Who sh Do not you tak have b "What capsule What s sules?
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes.	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low- ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia	Who sh Do not you tak have b "What capsule What s sules? Before
8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION I INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low- ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT	Who sh Do not you tak have by "What capsule What s sules? Before
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day.	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals.	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia 7 DRUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia D RUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., 	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you chici
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink.	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia DRUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 (e.g., cyclosporine). 	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you chicin provi
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia D RUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., 	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you • if you • if you • if you
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <i>Drug Interactions (7)</i>]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <i>Drug Interactions (7)</i>]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <i>Drug Interactions (7)</i>]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <i>Drug Interactions (7)</i>]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules with d	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia 7 DRUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 (e.g., cyclosportein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 (e.g., cyclosportein. Toxicities have also been reported when colchicine is administered with inhibitors of P-gp that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapami), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosportein.). Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 [See Contraindications (4)]. Combining these dual inhibitors of treatment with colchicine capsules and remain alert for signs and 	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you chici provi • if you vour er ab
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <i>Drug Interactions (7)</i>]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules.	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia O DRUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 (e.g., cyclosporine). Patients with renal on hepatic impairment should not be given colchicine capsules with drugs that inhibitors of P-glycoprotein and CYP3A4 (See <i>Contraindications</i> (4)]. Combining these dual inhibitors with colchicine capsules in patients with renal and hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. 	Who sh Do not you tak have by "What capsule What s sules? Before y abou if you of the you your er ab Tell you
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 2. Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CVP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia 7 DRUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 (e.g., cyclosporine). Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 (See <i>Contraindications</i> (4)]. Combining these dual inhibitors with colchicine capsules and remain alert for signs and symptoms of toxic reactions associated with increased colchicine exposure due to drug interactions. Signs and symptoms of col- 	Before • abou • if you • if you chicin provi • if you your er ab Tell you prescrip
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Prepanatoy 2. Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine. Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: elevopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Msculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: accospermia, oligospermia O DRUG INTERACTIONS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with linibitors of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with linibitors of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of CYP3A4 (e.g., cyclosportein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of CYP3A4 (e.g., cyclosportein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of CYP3A4 (e.g., cyclosportein. Toxicities have also been reported when colchicine is administered with inhibitors with colchicine capsules and remain alert for signs and symptoms of toxic reactions associated with increased colchicine exposure due to drug interactions. Signs and symptoms of colchicine toxicity. Pateints with renal on hepatie ingairment should not be given	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you • if you • if you • our er ab Tell you • Using
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 2. Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CVP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS	 PACKAGE LABEL PRINCIPAL DISPLAY *sections or subsections omitted from the full prescribing information are not listed. *sections or subsections have been reported with colchicine. These have been generally reversible by interrupting treatment or low-eing the dose of colchicine. Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Meurologicai: sensory motor neuropathy Dermatologicai: alopecia, maculopapular rash, purpura, rash Hematologicai: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletai: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis A productive: acoospermia, oligospermia A DRUGINTERACTIONS Motechicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with clarithromycin, a dual inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., capeforut), verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosportien, Toxicities have also been reported when colchicine is administered with clarithromycin, adual unbibitor of CYP3A4 (e.g., cyclosportien, depate). Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and hepatic impairment should not be given colchicine capsules with clarithromycin, signa and symptoms of colcineine toxicity. Ayoicans should ensure that patients are suitable candidates for treatment with colchicine capsules should be discontinued immediately. A. CYP3AE 	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you • if you • or vi • if you • or vi • if you • er ab Tell you prescrij
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 2. Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Over-	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. *Sections or subsections have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: addominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia DIRUG INTERACTIONS Cohicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine). Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 (See <i>Contraindications</i> (A)]. Combining these dual inhibitors with colchicine capsules and remain and hepatic impairment has resulted in life-threatening or fatal colchicine toxicity. An evaluate of toxic reactions associated with increased colchicine capsules in patients with renal and hepatit impairment should	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you chicin provi • if you your er ab Tell you prescrip • Using other
 8 USE IN SPECIFIC POPULATIONS 1. Use in Pregnancy 2. Labor and Delivery 3. Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS O.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP344 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Over-dosage (10)]. Colchicine capsules should be kept out of the reach of children. 5. Blood Dyscrasias	 PACKAGE LABEL PRINCIPAL DISPLAY *sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-eing the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Meurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hegatolitiary: elevated AST, elevated ALT Mesculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis A DRUG INTERACTIONS Dolichicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with chalitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., graperruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of P-glyCopyrotein and CyP3A4 (e.g., cyclosporine). Attents with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and propating informations of the gluculariandications of the fully calchicine toxicity. Mysicians should ensure that patients are suitable candidates for treatment with colchicine capsules and symptoms of colchicine toxicity. Mysicians should be avoided due to the potential for serious and life-threatening toxicity [See Warnings and Precautions (s.g.) and clinical Pharmacology (t2)). 	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you chici provi • if you your er ab Tell you prescri • Do no care
 8 USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <i>Drug Interactions</i> (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose Etal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See <i>Overdosage</i> (10)]. Colchicine capsules should be keen or the cach of children. 5.2 Biod Dyscrasias Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses.	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Neurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatobiliary: elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia 7 DRUG INTERACTIONS Tohchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of P-glycoprotein. Toxicities inpairment has resulted in life-threatening or fatal colchicine capsules with colchicine capsules and remain aller for signs and symptoms of toxic reactions associated with inhibitors of treatment with colchicine capsules and symptoms of toxic sections associated with increased colchicine exposure due to drug interactions. Signs and symptoms of ochic intervicity should be avoilated promptly and, if toxicity is suspected, colchicine capsules should be discontinue dimediately. Dyscians should nesure that patients are suitable candidates for treatment with colchicine capsules and remain aller for signs and symptoms of toxic reactions associated with incirceas	 Who sh Do not you tak have b "What capsule What s sules? Before abou if you chici, provi if you er ab Tell you prescrip Using other Do nacare Know
 B USE IN SPECIFIC POPULATIONS 1.1 Use in Pregnancy 2.2 Labor and Delivery 3.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WANNINGS AND PRECAUTIONS 5.1 Fatal Overdose Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Overdosage (10)]. Colchicine is should be kept out of the reach of children. 5.2 Blood Dyserasias Weylosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia have been reported with colchicine used in therapeutic doses. 	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Meurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Hentatological: elukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Heytabiliary: elevated AST, elevated ALT Musuloskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis A DRUG INTERACTIONS Olichicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities are been reported when colchicine is administered with colchicine capsules with drugs that inhibitor of CYP3A4 (e.g., cyclosporine). Roteins with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibitor of CYP3A4 (e.g., cyclosporine). Attents with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibitor of cyclosA4 (e.g., cyclosporine). Attents with renal or hepatic impairment should not be given colchicine capsules should be discontinued immediately. Attents with renal and hepatic impairment should not be given colchicine capsules should be discontinued immediately. Attents with renal and thora sported with incircitors to cyclos proves. Signs and symptoms of toxic reactions associated with incircitors capsules should be avaided for signs and symptoms of choic reactions associated	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you • if you • if you • or ou provi • if you • er ab Tell you prescri • Using other • Know show
 B USE IN SPECIFIC POPULATIONS Nuse in Nersing Mothers Use in Nursing Mothers FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CVP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdoses Fotal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Dverdosage (10)]. Colchicine capsules, and aplastic anemia have been reported with colchicine used in therapeutic doses. 5.3 Interactions with CYP3A4 and P-gp Inhibitors Because colchicine is a substrate for both the CYP3A4 metabolizing enzyme and the P-glycoprotein efflux transporter, inhibition of bither CYP3A4 and P-gp by dual inhibitors such as claritier of these athways may lead to colchicine related tocicity. Inhi	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. **Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Meurological: sensory motor neuropathy Beurological: elukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatological: elukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatological: elukopenia, granulocytopenia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: zoospermia, oligospermia DRUG INTERACTIONS On BUG INTERACTIONS On Budie in a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal frug interactions have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein and CYP3A4 (See <i>Contraindications</i> (4)]. Combining these dual inhibitors of CYP3A4 (seg. cyclosponie). Patients with renal or hepatic impairment thould not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 (See <i>Contraindications</i> (4)]. Combining these dual inhibitors of CYP3A4 (seg. cyclosponie). Patients with renal or hepatic impairment shale candidates for treatment with colchicine capsules and symptoms of cochicine capsules and CYP3A4 inhibitors (seg., clarit	 Who sh Do not you tak have by "What capsule What s sules? Before 1 abou if you if you other Do not other Using other Know show medi
 B USE IN SPECIFIC POPULATIONS 1.1 Use in Pregnancy 2.2 Labor and Delivery 3.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. Colchicine capsules are administered orally, without regard to meals. Colchicine capsules are administered orally, without regard to meals. Colchicine capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP344 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life threatening or tatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given colchicine capsules. 5. WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose Eatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Overdosage (10)]. Colchicine capsules should be kept out of the reach of children. 5.2 Blood Dyscrasis Myelosuppression, leukopenia, granulocytopenia, t	PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or lowering the dose of colchicine. Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Heurological: sensory motor neuropathy Heurological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hepatological: leukopenia, granulocytopenia, muscle weakness, muscle pain, rhabdomyolysis Argordetive: zoospermia, oligospermia D RUG INTERACTIONS On BUG INTERACTIONS On Bud Internation of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 and P-glycoprotein. Toxicities have been reported when colchicine is administered with inhibitors of CYP3A4 (e.g., cyclosporine). Patents with renal or hepstic impairment should not be give noclhicine capsules with drugs that inhibitor of cyrP3A4 (e.g., cyclosporine). Patents with sense that patients are suitable candidates for treatment with colchicine capsules and symptoms of colchicine capsules and CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, grapefruit juice, erythromycin, teozonitani uses of colchicine capsules and CYP3A4 inhibi	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you • if you • or vi • if you • or vi • using • other • Do no care • Know show medi • Espe • me
 B USE IN SPECIFIC POPULATIONS 1 Use in Nergenancy 2 Labor and Delivery 3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Overdosage (10)]. Colchicine capsules and hepatic impairment should not be given colchicine capsules. 5.3 Marking SAND PRECAUTIONS 5.4 Relat Overdoses Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Overdosage (10)]. Colchicine capsule should be kept out of the reach of children. 5.2 Rood Dyscrasias Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic an	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarthea, lactose intolerance, nausea, vomiting Meurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Henatological: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia Ottokiene is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with hichitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., org/cosporine). Ruetts with renal or hepatic impairment should not be given colchicine capsules with colchicine capsules should be evaluated promyting these dual inhibitors of CYP3A4 and P-glycoprotein of CYP3A4 and P-glycoprotein. Toxicities impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein. Ruetts with renal or hepatic impairment should not be given colchicine capsules should be discontinued immediately. A CYP3A4 Ruetts with renal or hepatic impairment should not be given colchicine capsules should be discontinued infine threatening or fatal colchicine toxicity. Ruetts with renal and patients are suitable candidates for treatment with colchicine capsules and precautions. Signs and symptoms of toxic reactions associated with increased colchicine capsules should be discontinued immediately. A CYP3A4 Ruetts with renal and the optical colchicine toxicity is suspected, colchicine capsules should be discontinued immed	Who sh Do not you tak have b "What capsule What s sules? Before • abou • if you • if you • or vi • if you • or vi • using • other • Do ne • abou • er ab Tell you prescrif • Using • other • Espe • medi • cyou
 B USE IN SPECIFIC POPULATIONS 8.1 Use in Pregnancy 8.2 Labor and Delivery 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 OUTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CVP3A4 inhibitors (See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Over-dosager (10)]. Colchicine capsules should be kept out of the reach of children. 5.3 Interactions with CYP3A4 and P-gg Inhibitors Bradia overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Over-dosager (10)]. Colchicine capsules should be kept out of the reach of children. 5.3 Interactions with CYP3A4 and P-gg Inhibitors E.3 Interactions with CYP3A4 and P-gg Inhibitors E.3 Interactions with CYP3A	 PACKAGE LABEL PRINCIPAL DISPLAY *sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarthea, lactose intolerance, nausea, vomiting Meurological: sensory motor neuropathy Dermatological: alopecia, maculopapular rash, purpura, rash Henatological: myopathy, elevated AST, elevated ALT Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Agroducitve: acoospermia, oligospermia Cholicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have also been reported when colchicine is administered with inhibitors of CYP3A4 tant my not be potent inhibitors of P-gp (e.g., graperfui julee, erythromycin, vergamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine). Aute substrate of the efflux transporter P-glycoprotein colchicine capsules with drugs that inhibit both P-glycoprotein. Toxicities have also been reported when colchicine is administered with inhibitors of CYP3A4 tant my not be potent inhibitors of CYP3A4 (e.g., cyclosporine). Aute substrate of the efflux transporter D-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclosporine). Aryyssa (See Contraindications (A)). Combining these dual inhibitors with colchicine capsules in patients with renal and hepatic impairment should not be given colchicine capsules should be discontinued inmediately. A CYP3A4 [See Contraindications (A)]. Combining these dual inhibitors (e.g., clarithromycin, ketoconazole, grapefruit juice, erythromycin, vergamil, et. (b.g., clarithromycin, ketoconazole, grapefruit ju	Who sh Do not you tak have b "What capsule What s sules? Before abou if you othic provi other Do no care Know show medi Espe other
 B USE IN SPECIFIC POPULATIONS 1 Use in Nergenancy 2 Labor and Delivery 3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. 2 DOSAGE AND ADMINISTRATION 2.1 Gout Prophylaxis For prophylaxis of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. 3 DOSAGE FORMS AND STRENGTHS 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitres [See Durg Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdoses Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Over-dosager (1)]. Colchicine capsules should be kept out of the reach of children. 5.3 Interactions with CYP3A4 and P-gp Inhibitors Because colchicine is a substrate tor both the CYP3A4 mathetion of children. 5.3 Interactions with CYP3A4 and P-gp Inhibitors Because colchicine is a substrate tor both the CYP3A4 mathetion of both CYP3A4 and P-gp updroprotein influx transporter, inhibition of either of these pathways may lead to colchicine capsules in onithor or both CYP3A4 and	PACKAGE LABEL PRINCIPAL DISPLAY **Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-	Who sh Do not you tak have by "What capsule What s sules? Before abou if you other Do no care Know show medi Esper cyo
 B USE IN SPECIFIC POPULATIONS B.1 Use in Nursing Mothers EVLL PRESCRIBING INFORMATION TUL PRESCRIBING INFORMATION INDICATIONS AND USAGE Colchicine capsules are indicated for prophylaxis of gout flares in adults. Limitations of use: The safety and effectiveneess of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. DOSAGE AND ADMINISTRATION Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. DOSAGE AND ADMINISTRATION Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. DOSAGE AND ADMINISTRATION Colchicine capsules of gout flares, the recommended dosage of colchicine capsules is 0.6 mg once or twice daily. The maximum dose is 1.2 mg per day. Colchicine capsules are administered orally, without regard to meals. DOSAGE FORMS AND STRENGTHS O.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. 4 CONTRAINDICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors [See <i>Drug Interactions</i> (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in IIf-treatening or fatal colchicite toxity. Patients with both renal and hepatic impairment should not be given colchicine capsules. 5 WARNINGS AND PRECAUTIONS 5.1 Fatal Overdose Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See <i>Overdosage</i> (10)]. Colchicine capsules should be kept out of the reach of children. 5.2 Hiood Dyserasia	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. *Sections or subsections nave been reported with colchicine. These have been generally reversible by interrupting treatment or low- ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Meurologicai: sensory motor neuropathy Dermatologicai: alopecia, maculopapular rash, purpura, rash Henatologicai: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hegatobiliary: elevated AST, elevated ALT Musculoseletai: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia 7 DRUG INTERACTIONS Motionie is administered with inhibitors of CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-90 (e.g., graperiut) isice, erythromycin, verapamily, or inhibitors of P-90 that may not be potent inhibitors of P-90 (e.g., graperiut) isice, erythromycin, verapamily, or inhibitors of CYP3A4 that may not be potent inhibitors of CYP3A4 (Sec Contraindications (4)). Combining these dual inhibitors with colchicine capsules in patients with renal and hepatic impairment should on the given colchicine capsules in patients with renal and hepatic impairment should on the given colchicine capsules in patients with renal and hepatic impairment should ensorted the additates for treatment with colchicine capsules and symptoms of coichichic capsules should be evaluated promptly and, if toxicity is suspected, colchicine capsules and symptoms of coichichic is daministers of P-90 coprotein (E.g., Carithromycin, ketoconazole, grapefruit juice, erythromycin, veargamil, etc.) should be avolided due to the pot	 Who sheet Do not you take have be "What capsule What signed Before about if you or fyou <
 B USE IN SPECIFIC POPULATIONS B.1 Use in Nerspanacy Labor and Delivery Labor and Delivery Lincitations of use: The safety and effectiveness of colchicine capsules for acute treatment of gout flares during prophylaxis has not been studied. Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. DOSAGE AND ADMINISTRATION Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. DOSAGE AND ADMINISTRATION Colchicine capsules are not an analgesic medication and should not be used to treat pain from other causes. DOSAGE AND ADMINISTRATION Colchicine capsules are administered orally, without regard to meals. DOSAGE FORMS AND STRENGTHS Colchicine capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. DOSAGE FORMS AND STRENGTHS Of mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink. ColCHICINIC SIGN DY DEFECTIONS DATINICATIONS Patients with renal or hepatic impairment should not be given colchicine capsules with rough to the pagicoprotein and CP3A4 inhibitos [See Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment should not be given colchicine capsules. S WARININGS AND PRECAUTIONS S. ARNINGS AND PRECAUTIONS S. ARNINGS AND PRECAUTIONS S. A Patio Verdose Fald Overdose Fald overdose, both accidental and intentional, have been reported in adults and children who have ingested colchicine [See Orecdosage (10)]. Colchicine capsules should be kept out of the reach of children. S. Allou Overdose S. Allou Overdose S. Allou Overdose S. Allou Overdose Because colchicine is a substrate for both the CYP3A4 metaboli	 PACKAGE LABEL PRINCIPAL DISPLAY *Sections or subsections omitted from the full prescribing information are not listed. The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-ering the dose of colchicine: Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting Meurologicai: sensory motor neuropathy Dermatologicai: alopecia, maculopapular rash, purpura, rash Hematologicai: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia Hegatohiliary: elevated AST, elevated ALT Msculoskeletai: moyapathy, elevated CKF, myotonia, muscle weakness, muscle pain, rhabdomyolysis Reproductive: azoospermia, oligospermia 7 DRUG INTERACTIONS Motionie is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., raprefurit juice, erythromycin, verapamil), or inhibitors of P-gp that any not be potent inhibitors of P-gp (e.g., raprefurit juice, erythromycin, verapamil), or inhibitors of P-gp that any not be potent inhibitors of P-gp (e.g., raprefurit juice, erythromycin, verapamil), or inhibitors of P-gp that any not be potent inhibitors of P-gp (e.g., raprefurit juice, erythromycin, verapamil, or inhibitors of P-gp that any not be potent inhibitors of P-gp (e.g., raprefurit juice, erythromycin, verapamil, et al colchicine tocivity. Physicians should ensure that patients are suitable infertineation or attal colchicine tocivity. Physicians should ensure that patients are suitable candidates for treatment with colchicine capsules and erroin al erytony (ray). A CYP3A4 (Sac Contraindications (4)). Combining these dual inhibitors	Who sh Do not you tak have by "What capsule What s sules? Before abou if you other Do no care Know show medi Esper cyo

Four pharmacokinetic studies evaluated the effects of co-administration of voriconazole (200 mg BID), fluconazole (200 mg QD),

drugs at the tested does without a need for dose adjustment. However, these results should not be extrapolated to other co-admini-

crosses the human placenta. Developmental studies in animals were not conducted with colchicine capsules, however published

animal reproduction and development studies with colchicine demonstrated embryofetal toxicity, teratogenicity, and altered postnatal

development at exposures within or above the clinical therapeutic range. Colchicine should be used during pregnancy only if the

istered drugs [See Drug-Drug Interactions (7.1, 7.2) and Pharmacokinetics (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Use in Pregnancy

6 ADVERSE REACTIONS

seinsden eniningio.

Gastrointestinal disorders are the most common adverse reactions with colchicine. They are often the first signs of toxicity and may indicate that the colchicine dose needs to be reduced or therapy stopped. These include diarrhea, nausea, vomiting, and abdominal pair

Colchicine has been reported to cause neuromuscular toxicity, which may present as muscle pain or weakness [see Warnings and Precautions (5.4)].

Pregnancy Category C. There are no adequate and well-controlled studies with colchicine capsules in pregnant women. Colchicine Toxic manifestations associated with colchicine include myelosuppression, disseminated intravascular coagulation, and injury to cells in the renal, hepatic, circulatory, and central nervous system. These most often occur with excessive accumulation or overdosage [see Overdosage (10)].

How should I take colchicine capsules?

- take it.

sules can cause serious side effects or death if levels of colhigh in your body.

lares

sules are not a pain medicine and it should not be taken to ted to other conditions unless specifically for those condi-

- colchicine capsules with other medicines unless your healthr tells vou to.
- edicines you take. Keep a list of your medicines with you to ealthcare provider and pharmacist each time you get a new
- - that may affect how your liver works (CYP3A4 inhibitors) ine (Neoral®, Gengraf®, Sandimmune®) ol lowering medicines

- Colchicine capsules can be taken with or without food. · If you take too much colchicine capsules, call your healthcare provider or go to the nearest hospital emergency room right away.

Medication Guide

Colchicine (kol' chi seen) Capsules

ost important information I should know about colchicine

in medicines with colchicine capsules can cause your level of be too high, especially if you have kidney or liver problems. Ithcare provider about all your medical conditions, including kidney or liver problems. Your dose of colchicine capsules be changed.

nes that you take for a short period of time, such as antibiotract with colchicine capsules and cause serious side effects

hicine capsules?

sules are a prescription medication used to prevent gout

n if colchicine capsules are safe and effective for the treat-

if colchicine capsules are safe and effective in children.

ot take colchicine capsules?

Ichicine capsules if you have liver and kidney problems and in other medicines. Serious side effects, including death, ported in these people even when taken as directed. See nost important information I should know about colchicine

tell my healthcare provider before taking colchicine cap-

e colchicine capsules, tell your healthcare provider:

- our medical conditions
- idney or liver problems
- egnant or plan to become pregnant. It is not known if colsules can harm your unborn baby. Talk to your healthcare ou are pregnant or plan to become pregnant.
- reastfeeding or plan to breastfeed. Colchicine can pass into nilk and may harm your baby. Talk to your healthcare providbest way to feed your baby if you take colchicine capsules.
- hcare provider about all the medicines you take, including ver-the-counter medicines, vitamins, or herbal supplements.
- icine capsules with certain other medicines can affect each ng serious side effects and/or death.
- Il your healthcare provider if you take:

hcare provider or pharmacist if you are not sure if you take edicines listed above. This is not a complete list of all the medicines that can affect colchicine capsules.

• Take colchicine capsules exactly as your healthcare provider tells you to

Do not stop taking colchicine capsules unless your healthcare provider

tells you to.

- · If you miss a dose of colchicine capsules, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take the next dose at your regular time. Do not take 2 doses at the same time.
- If you have a gout flare while taking colchicine capsules, tell your healthcare provider.

What should I avoid while taking colchicine capsules?

 Avoid eating grapefruit or drinking grapefruit juice while taking colchicine capsules. It can increase your chances of getting serious side effects.

What are the possible side effects of colchicine capsules?

Colchicine capsules can cause serious side effects or death. See "What is the most important information I should know about colchicine capsules?'

Get medical help right away, if you have:

- unusual bleeding or bruising
- increased infections
- weakness or fatigue
- muscle weakness or pain
- numbness or tingling in your fingers or toes
- pale or gray color to your lips, tongue, or palms of your hands severe diarrhea or vomiting

The most common side effects of colchicine capsules include abdominal pain, diarrhea, nausea, and vomiting.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of colchicine capsules. For more information ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store colchicine capsules?

- Store colchicine capsules at room temperature between 68° to 77°F (20° to 25°C).
- Keep colchicine capsules in a tightly closed container.
- Keep colchicine capsules out of the light and away from moisture.

Keep colchicine capsules and all medicines out of the reach of children.

General information about the safe and effective use of colchicine capsules.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take colchicine capsules for a condition for which it was not prescribed. Do not give colchicine capsules to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about colchicine capsules. If you would like more information, talk to your pharmacist or healthcare provider for information about colchicine capsules that is written for health professionals.

For more information, go to www.west-ward.com or call 1-800-962-8364.

What are the ingredients in colchicine capsules?

Active Ingredient: Colchicine

Inactive Ingredients: colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. The capsule shell contains gelatin, purified water, titanium dioxide, erythrosine, Brilliant Blue FCF and Quinoline Yellow.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Distr. by: West-Ward Pharmaceuticals Corp. Eatontown, NJ 07724

C50000043/01

February 2018

- potential benefit justifies the potential risk to the fetus.
- 8.2 Labor and Delivery
- The effect of colchicine on labor and delivery is unknown.

8.3 Use in Nursing Mothers

Colchicine is excreted into human milk. Limited information suggests that infants exclusively breastfed receive less than 10 percent of the maternal weight-adjusted dose. While there are no published reports of adverse effects in breast-feeding infants of mothers taking colchicine, colchicine can affect gastrointestinal cell renewal and permeability. Caution should be exercised and breastfeeding infants should be observed for adverse effects when colchicine capsules is administered to a nursing woman.

8.4 Pediatric Use

Gout is rare in pediatric patients; the safety and effectiveness of colchicine capsules in pediatric patients has not been evaluated in . controlled studies

8.5 Geriatric Use

Because of the increased incidence of decreased renal function in the elderly population, and the higher incidence of other co-morbid conditions in the elderly population requiring the use of other medications, reducing the dosage of colchicine when elderly patients are treated with colchicine should be carefully considered.

8.6 Renal Impairment

No dedicated pharmacokinetic study has been conducted using colchicine capsules in patients with varying degrees of renal impair ment. Colchicine is known to be excreted in urine in humans and the presence of severe renal impairment has been associated with colchicine toxicity. Urinary clearance of colchicine and its metabolites may be decreased in patients with impaired renal function. Dose reduction or alternatives should be considered for the prophylaxis of gout flares in patients with severe renal impairment. Colchicine is not effectively removed by hemodialysis. Patients who are undergoing hemodialysis should be monitored carefully for colchicine toxicity.

8.7 Hepatic Impairmen

No dedicated pharmacokinetic study using colchicine capsules has been conducted in patients with varying degrees of hepatic impairment. Colchicine is known to be metabolized in humans and the presence of severe hepatic impairment has been associated with colchicine toxicity. Hepatic clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment.

Dose reduction or alternatives should be considered for the prophylaxis of gout flares in patients with severe hepatic impairment

9 DRUG ABUSE AND DEPENDENCE

Tolerance, abuse, or dependence from colchicine has not been reported.

10 OVERDOSAGE


The dose of colchicine that would induce significant toxicity for an individual is unknown. Fatalities have been reported in patients The doce of order international mode of a mode of a second provide and the second of t have milder adverse reactions, such as gastrointestinal symptoms, whereas those who ingested from 0.5 to 0.8 mg/kg had more severe adverse reactions, including myelosuppression. There was 100% mortality among patients who ingested more than 0.8 mg/kg.

- The first stage of acute colchicine toxicity typically begins within 24 hours of ingestion and includes gastrointestinal symptoms such as abdominal pain, nausea, vomiting, diarrhea, and significant fluid loss, leading to volume depletion. Peripheral leukocytosis may also be seen
- · Life-threatening complications occur during the second stage, which occurs 24 to 72 hours after drug administration, attributed to multi-organ failure and its associated consequences. Death usually results from respiratory depression and cardiovascular collapse. If the patient survives, recovery of multi-organ injury may be accompanied by rebound leukocytosis and alopecia starting about 1 week after the initial ingestio
- Treatment of colchicine overdose should begin with gastric lavage and measures to prevent shock. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. Colchicine is not effectively removed by hemodialysis [See Pharmacokinetics (12.3)].

DESCRIPTION

Colchicine is an alkaloid obtained from the plant colchicum autumnale

The chemical name for colchicine is (S)-N-(5.6.7.9- tetrahydro-1.2.3.10-tetramethoxy-9 oxobenzolfalheptalen-7-yl) acetamide. The structural formula is represented below



M.W. 399.44

Colchicine consists of pale yellow scales or powder; it darkens on exposure to light. Colchicine is soluble in water, freely soluble in alcohol, and slightly soluble in ether

Colchicine capsules are supplied for oral administration. Each capsule contains 0.6 mg Colchicine and the following inactive ingredients: colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. The capsule shell contains gelatin, purified water, titanium dioxide, erythrosine, Brilliant Blue FCF and Quinoline Yellow

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Colchicine's effectiveness as a treatment for gout has been postulated to be due to its ability to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of neutrophils to sites of inflammation. Colchicine also interferes with the inflammasome complex found in neutrophils and monocytes that mediates interleukin-1 β (IL-1 β) activation.

12.3 Pharmacokinetics

Absorption

In healthy adults, colchicine capsules when given orally reached a mean C_{max} of 3 ng/mL in 1.3 h (range 0.7 to 2.5 h) after 0.6 mg Blood Dyscrasias single dose administration

Absolute bioavailability is reported to be approximately 45%

Administration with food has no effect on the rate or extent of colchicine absorption

Colchicine is not effectively removed by hemodialysis

Distribution

Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg. Colchicine binding to serum protein is about 39%, primarily to albumin. Colchicine crosses the placenta and distributes into breast milk [See Pregnancy (8.1) and Nursing Mothers (8.3)].

Metabolism

A published in vitro human liver microsome study showed that about 16% of colchicine is metabolized to 2-0-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively) by CYP3A4. Glucuronidation is also believed to be a metabolic pathway for colchicine.

Excretion

In a published study in healthy volunteers, 40 to 65% of the total absorbed dose of colchicine (1 mg administered orally) was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also believed to play a role in colchicine elimination. Colchicine is a substrate of P-gp and P-gp efflux is postulated to play an important role in colchicine disposition. Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).

Special Populations

There is no difference between men and women in the pharmacokinetic disposition of colchicine.

Pediatric Patients: Pharmacokinetics of colchicine was not evaluated in pediatric patients.

Elderly: Pharmacokinetics of colchicine have not been determined in elderly patients. A published report described the pharmacoki reactions of the parameters of containing have been been been med and only parameters of parameters of the parameters of to 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males. It is possible that the higher exposure in the elderly subjects was due to decreased renal function.

Renal impairment: Pharmacokinetics of colchicine in patients with mild and moderate renal impairment is not known. A published report described the disposition of colchicine (1 mg) in young adult men and women patients who had end-stage renal disease requiring dialysis compared to patients with normal renal function. Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hrs vs. 4.4 hrs) as compared to subjects with normal renal function [See Renal Impairment (8.6)].

Hepatic impairment: Published reports on the pharmacokinetics of intravenous colchicine in patients with severe chronic liver disease, as well as those with alcoholic or primary biliary cirrhosis, and normal renal function suggest wide inter-patient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with primary biliary cirrhosis, no consistent trends were noted [See Hepatic Impairment] (8.7)]. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).

Drug Interactions

Pharmacokinetic studies evaluating changes in systemic levels of colchicine when co-administered with CYP3A4 inhibitors in healthy volunteers have been conducted with colchicine capsules. While voriconazole 200 mg BID for 5 days (considered a strong CYP3A4 inhibitor) and cimetidine 800 mg BID for 5 days (considered a weak CYP3A4 inhibitor) did not cause any changes in colchicine systemic levels, fluconazole 200 mg QD for 4 days with a 400 mg loading dose (considered a moderate CYP3A4 inhibitor) increased colchicine AUC by 40%. As voriconazole, cimetidine, and fluconazole are known as CYP3A4 inhibitors that do not inhibit P-op, these studies show that CYP3A4 inhibition by itself may not lead to clinically significant increases in colchicine systemic levels in humans, and P-gp inhibition in addition to CYP3A4 inhibition may be necessary for clinically meaningful interactions of colchicine. However, based on published case reports that indicate the presence of colchicine toxicity when colchicine is co-administered with strong to moderate CYP3A4 inhibitors such as clarithromycin, erythromycin, grapefruit juice, etc., as well as the 40% increase in systemic levels of colchicine observed with concomitantly administered fluconazole (a moderate CYP3A4 inhibitor that is not known to inhibit P-gp) in a drug-drug interaction study, the drug-drug interaction potential of colchicine with strong or moderate CYP3A4 inhibitors that do not inhibit P-gp cannot be ruled out completely

Co-administration of colchicine capsules with propafenone (a P-gp inhibitor) at 225 mg BID for 5 days, in a pharmacokinetic study in healthy volunteers, did not cause any changes in systemic levels of colchicine. This indicates that propafenone can be administered with colchicine capsules without any dose adjustment. However, these results should not be extrapolated to other P-op inhibitors as colchicine is known to be a substrate for P-gp and case reports of colchicine toxicity associated with the co-administration of P-gp inhibitors such as cyclosporine have been published.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis

Carcinogenicity studies of colchicine have not been conducted. Due to the potential for colchicine to produce aneuploid cells (cells with an unequal number of chromosomes), colchicine presents a theoretical increased risk of malionancy

Mutagenesis

Published studies demonstrated that colchicine was negative for mutagenicity in the bacterial reverse mutation assay. However, in vitro chromosomal aberration assays demonstrated the formation of micronuclei following colchicine treatment. Because published studies demonstrated that colchicine induces aneuploidy through the process of mitotic nondisjunction without structural DNA changes, colchicine is not considered clastogenic, although micronuclei are formed

pairment of Fertility

There were no studies of the effects of colchicine capsules on fertility. However, published nonclinical studies have demonstrated that colchicine-induced disruption of microtubule formation affects meiosis and mitosis. Published reproductive studies with colchicine reported abnormal sperm morphology and reduced sperm counts in males, and interference with sperm penetration, second meiotic division, and normal cleavage in females

Case reports and epidemiology studies in human male subjects on colchicine therapy indicate that infertility from colchicine is rare A case report indicated that azoospermia was reversed when therapy was stopped. Case reports and epidemiology studies in female subjects on colchicine therapy have not established a clear relationship between colchicine use and female infertility

14 CLINICAL STUDIES

The evidence for the efficacy of colchicine in patients with chronic gout is derived from the published literature. Two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of gout flares in patients with gout initiating treatment with urate lowering therapy. In both trials, treatment with colchicine decreased the frequency of gout flares.

16 HOW SUPPLIED/STORAGE AND HANDLING

NDC 0143-3018-30: Bottle of 30 Capsules

NDC 0143-3018-01: Bottle of 100 Capsules

NDC 0143-3018-10: Bottle of 1000 Capsules

17 PATIENT COUNSELING INFORMATION

Protect from light and moisture

Store at 20° to 25°C (68° to 77°F), [See USP Controlled Room Temperature]

Advise the patient to read the FDA-approved patient labeling (Medication Guide)

schedule. However, if a dose is skipped, the patient should not double the next dose

colchicine. Colchicine capsules should be kept out of the reach of children

should not be consumed during treatment with colchicine capsules.

16.1 How Supplied

16.2 Storage

Dosing Instructions

Fatal Overdose

cine capsules

Drug and Food Interactions

and seek medical evaluation immediately

West-Ward Pharmaceuticals Corp.

ntown. NJ 07724

C50000043/01

Colchicine capsules, 0.6 mg are No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink.

If a dose of colchicine capsules is missed, advise the patient to take the dose as soon as possible and then return to the normal dosing

Advise the patient that fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested

Advise patients that bone marrow depression with agranulocytosis, aplastic anemia, and thrombocytopenia may occur with colchi-

Advise patients that many drugs or other substances may interact with colchicine capsules and some interactions could be fatal. Therefore, patients should report to their healthcare provider all of the current medications they are taking, and check with their healthcare provider before starting any new medications, including short-term medications such as antibiotics. Patients should also be advised to report the use of non-prescription medication or herbal products. Grapefruit and grapefruit juice may also interact and

Advise patients that muscle pain or weakness, tingling or numbness in fingers or toes may occur with colchicine capsules alone or when it is used with certain other drugs. Patients developing any of these signs or symptoms must discontinue colchicine capsules



HIGHLIGHTS OF PRESCRIBING INFORMATION Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine (5.2, 5.3, 5.4, 6, 10) Rx Only 19 C These highlights do not include all the information needed to use MITIGARE® safely and effectively. See full prescribin • Drug interaction with dual P-gp and CYP3A4 inhibitors: Co-administration of colchicine with dual P-gp and CYP3A4 inhibitors has resulted in life-threatening interactions and death (5.3, 7). Neuromuscular toxicity: Myotoxicity including rhabdomyolysis may occur especially in combination with other drugs known to $\ensuremath{\mathsf{MITIGARE}}\xspace^{\ensuremath{\mathsf{R}}\xspace}$ (colchicine) capsules, for oral use cause this effect. Consider temporary interruption or discontinuation of MITIGARE® (5.4, 7). Initial U.S. Approval: 1961 ADVERSE REACTIONS -- INDICATIONS AND USAGE The most commonly reported adverse reactions with colchicine are gastrointestinal symptoms, including diarrhea, nausea, vomiting, · MITIGARE® is indicated for prophylaxis of gout flares in adults (1) and abdominal pain (6) Limitations of use To report SUSPECTED ADVERSE REACTIONS, contact Hikma Americas, Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or The safety and effectiveness of MITIGARE® for acute treatment of gout flares during prophylaxis has not been studied www.fda.gov/medwatch MITIGARE® is not an analgesic medication and should not be used to treat pain from other causes. -- DRUG INTERACTIONS Co-administration of P-gp or CYP3A4 inhibitors or inhibitors of both P-gp and CYP3A4 (e.g., clarithromycin or cyclosporine) have been reported to lead to colchicine toxicity. The potential for drug-drug interactions must be considered prior to and during therapy. -- DOSAGE AND ADMINISTRATION 0.6 mg (one capsule) once or twice daily (2). Maximum dose 1.2 mg/day Concomitant use of MITIGARE® and inhibitors of CYP3A4 or P-gp should be avoided if possible. If co-administration of MITI- $\mathsf{MITIGARE}^{\textcircled{B}}$ is administered orally, without regard to meals (2) GARE® and an inhibitor of CYP3A4 or P-gp is necessary, the dose of MITIGARE® should be reduced and the patient should be - DOSAGE FORMS AND STRENGTHS monitored carefully for colchicine toxicity (7, 12.3). are too high in your body. • 0.6 mg Capsules (3). -- USE IN SPECIFIC POPULATIONS - CONTRAINDICATIONS . In the presence of renal or hepatic impairment, patients should be monitored closely and dose adjustment should be considered as • Patients with renal or hepatic impairment should not be given MITIGARE® in conjunction with drugs that inhibit both P-gp and necessary (8.6, 8.7). CYP3A4 (4). Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (8.1) Nursing Mothers: Caution should be exercised when administered to a nursing woman (8.3).
 Geriatric Use: The recommended dose of colchicine should be based on renal/hepatic function (8.5). problems Patients with both renal and hepatic impairment should not be given MITIGARE[®] (4) WARNINGS AND PRECAUTIONS See 17 for PATIENT COUNSELING INFORMATION and Medication Guide • Fatal overdoses have been reported with colchicine in adults and children. Keep MITIGARE® out of the reach of children (5.1. 10). Blood dyscrasias: myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, and aplastic ane Revised: 02/2018 to be changed (5.2). FULL PRESCRIBING INFORMATION: CONTENTS' 8.4 Pediatric Use 8.5 Geriatric Use8.6 Renal Impairment or death INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION 8.7 Hepatic Impairmen 2.1 Gout Prophylaxis 3 DOSAGE FORMS AND STRENGTHS What is MITIGARE®? DRUG ABUSE AND DEPENDENCE 10 OVERDOSAGE 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY รอเทรุตรา (อุกเวเกวเดว) ฃฐหหมา เพ adults. 5.1 Fatal Overdose 5.2 Blood Dyscrasias 12.1 Mechanism of Action 12.3 Pharmacokinetics 5.3 Interactions with CYP3A4 and P-gp Inhibitors **13 NONCLINICAL TOXICOLOGY** 5.4 Neuromuscular Toxicity enesis, Mutagenesis, Impairment of Fertility 13.1 Carcinoo acute gout flares 6 ADVERSE REACTIONS 14 CLINICAL STUDIES DRUG INTERACTIONS 16 HOW SUPPLIED/STORAGE AND HANDLING 7.1 CYP3A4 16.1 How Supplied P-glycoprot 16.2 Sto 16.2 Storage 17 PATIENT COUNSELING INFORMATION 7.3 HMG-CoA Reductase Inhibitors and Fibrates 7.4 Drug-Drug Interaction Studies 8 USE IN SPECIFIC POPULATIONS MEDICATION GUIDE PRINCIPAL DISPLAY PANEL 8.1 Use in Pregnancy8.2 Labor and Delivery *Sections or subsections omitted from the full prescribing information are not listed. 8.3 Use in Nursing Mothers FULL PRESCRIBING INFORMATION ering the dose of colchicine INDICATIONS AND USAGE Digestive: abdominal cramping, abdominal pain, diarrhea, lactose intolerance, nausea, vomiting MITIGABE® (colchicine) capsules are indicated for prophylaxis of gout flares in adults Neurological: sensory motor neuropathy Limitations of use: The safety and effectiveness of MITIGARE® for acute treatment of gout flares during prophylaxis has not been Dermatological: alopecia, maculopapular rash, purpura, rash Hematological: leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, aplastic anemia MITIGARE® is not an analgesic medication and should not be used to treat pain from other causes Hepatobiliary: elevated AST, elevated ALT 2 DOSAGE AND ADMINISTRATION Musculoskeletal: myopathy, elevated CPK, myotonia, muscle weakness, muscle pain, rhabdomyolysis 2.1 Gout Prophylaxis Reproductive: azoospermia, oligospermia For prophylaxis of gout flares, the recommended dosage of MITIGARE® is 0.6 mg once or twice daily. The maximum dose is 1.2 To report SUSPECTED ADVERSE REACTIONS, contact Hikma Americas, Inc. at 1-800-962-8364 or FDA at 1-800-FDA-1088 or mg per day. www.fda.gov/medwa MITIGARE® is administered orally, without regard to meals 7 DRUG INTERACTIONS 3 DOSAGE FORMS AND STRENGTHS Colchicine is a substrate of the efflux transporter P-glycoprotein (P-gp), and the CYP3A4 metabolizing enzyme. Fatal drug interactions have been reported when colchicine is administered with clarithromycin, a dual inhibitor of CYP3A4 and P-glycoprotein. Toxicities 0.6 mg capsules - No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink have also been reported when colchicine is administered with inhibitors of CYP3A4 that may not be potent inhibitors of P-gp (e.g., 4 CONTRAINDICATIONS grapefruit juice, erythromycin, verapamil), or inhibitors of P-gp that may not be potent inhibitors of CYP3A4 (e.g., cyclospo Patients with renal or hepatic impairment should not be given MITIGARE® with drugs that inhibit both P-glycoprotein and CYP3A4 Patients with renal or hepatic impairment should not be given MITIGARE[®] with drugs that inhibit both P-glycoprotein and CYP3A4 [see Contraindications (4)]. Combining these dual inhibitors with MITIGARE[®] in patients with renal and hepatic impairment has inhibitors [see Drug Interactions (7)]. Combining these dual inhibitors with colchicine in patients with renal or hepatic imp has resulted in life-threatening or fatal colchicine toxicity resulted in life-threatening or fatal colchicine toxicity. Patients with both renal and hepatic impairment should not be given MITIGARE® Physicians should ensure that patients are suitable candidates for treatment with MITIGARE® and remain alert for signs and symptoms of toxic reactions associated with increased colchicine exposure due to drug interactions. Signs and symptoms of colchicine 5 WARNINGS AND PRECAUTIONS toxicity should be evaluated promptly and, if toxicity is suspected, MITIGARE® should be discontinued immediately. 5.1 Fatal Overdos 7.1 CYP3A4 Fatal overdoses, both accidental and intentional, have been reported in adults and children who have ingested colchicine [see Over-The concomitant use of MITIGARE® and CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole, grapefruit juice, erythromycin, verdosage (10)]. MITIGARE® should be kept out of the reach of children. provider tells you to. apamil, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and 5.2 Blood Dyscrasias Clinical Pharmacology (12)]. Myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia have been reported with If co-administration of MITIGARE® and a CYP3A4 inhibitor is necessary, the dose of MITIGARE® should be adjusted by either reducing the daily dose or reducing the dose frequency, and the patient should be monitored carefully for colchicine toxicity [see Clinical Pharmacology (12)]. colchicine used in therapeutic doses medicine. 5.3 Interactions with CYP3A4 and P-gp Inhibitors 7.2 P-glycoproteir Because colchicine is a substrate for both the CYP3A4 metabolizing enzyme and the P-glycoprotein efflux transporter, inhibition of either of these pathways may lead to colchicine-related toxicity. Inhibition of both CYP3A4 and P-gb vala inhibitors such as clarithromycin has been reported to produce life-threatening or fatal colchicine toxicity due to significant increases in systemic The concomitant use of MITIGARE® and inhibitors of P-glycoprotein (e.g. clarithromycin, ketoconazole, cyclosporine, etc.) should be avoided due to the potential for serious and life-threatening toxicity [see Warnings and Precautions (5.3) and Clinical Pharmacology colchicine levels. Therefore, concomitant use of MITIGARE® and inhibitors of CYP3A4 or P-glycoprotein should be avoided [see Drug Interactions (7)]. If avoidance is not possible, reduced daily dose should be considered and the patient should be monitored closely (12)]. · antibiotics If co-administration of MITIGARE® and a P-gp inhibitor is necessary, the dose of MITIGARE® should be adjusted by either reducing for colchicine toxicity. Use of MITIGARE® in conjunction with drugs that inhibit both P-gp and CYP3A4 is contraindicated in patients with renal or hepatic impairment [see Contraindications (4)]. the daily dose or reducing the dose frequency, and the patient should be monitored carefully for colchicine toxicity [see Clinical Pharmacology (12)]. 5.4 Neuromuscular Toxicity 7.3 HMG-CoA Reductase Inhibitors and Fibrates Neuromuscular toxicity and rhabdomyolysis have been reported from chronic treatment with colchicine in therapeutic doses, espe-Some drugs such as HMG-CoA reductase inhibitors and fibrates may increase the risk of myopathy when combined with MITIGARE®. cially in combination with other drugs known to cause this effect. Patients with impaired renal function and elderly patients (even those with normal renal and hepatic function) are at increased risk. Once colchicine treatment is ceased, the symptoms generally Complaints of muscle pain or weakness could be an indication to check serum creatinine kinase levels for signs of myopathy. How should I take MITIGARE®? resolve within 1 week to several months. 7.4 Drug-Drug Interaction Studies ADVERSE REACTIONS 6 Four pharmacokinetic studies evaluated the effects of co-administration of voriconazole (200 mg BID), fluconazole (200 mg QD), cimetidine (800 mg BID), and propatenone (225 mg BID) on systemic levels of occhiciene. Colchicine can be administered with these drugs at the tested doses without a need for dose adjustment. However, these results should not be extrapolated to other co-admin-Gastrointe stinal disorders are the most common adverse reactions with colchicine. They are often the first signs of toxicity and may indicate that the colchicine dose needs to be reduced or therapy stopped. These include diarrhea, nausea, vomiting, and abdominal istered drugs [see Drug-Drug Interactions (7.1, 7.2) and Pharmacokinetics (12.3)] 8 USE IN SPECIFIC POPULATIONS Colchicine has been reported to cause neuromuscular toxicity, which may present as muscle pain or weakness [see Warnings and Precautions (5.4)]. 8.1 Use in Pregnancy Pregnancy Category C. There are no adequate and well-controlled studies with MITIGARE® in pregnant women. Colchicine crosses

Toxic manifestations associated with colchicine include myelosuppression, disseminated intravascular coagulation, and injury to cells in the renal, hepatic, circulatory, and central nervous system. These most often occur with excessive accumulation or overdosage [see Overdosage (10)]

The following reactions have been reported with colchicine. These have been generally reversible by interrupting treatment or low-

 Take MITIGARE[®] exactly as your healthcare provider tells you to take it. • MITIGARE® can be taken with or without food.

- to.

the human placenta. Developmental studies in animals were not conducted with MITIGARE[®], however published animal reproduction and development studies with colchicine demonstrated embryofetal toxicity, teratogenicity, and altered postnatal development at

exposures within or above the clinical therapeutic range. Colchicine should be used during pregnancy only if the potential benefit

ustifies the potential risk to the fetus

Medication Guide

MITIGARE® (mīt-ah-gär-ay) Capsules

Rx only

What is the most important information I should know about MITIGARE®?

MITIGARE® can cause serious side effects or death if levels of MITIGARE®

• Taking certain medicines with MITIGARE® can cause your level of MITIGARE® to be too high, especially if you have kidney or liver

 Tell your healthcare provider about all your medical conditions, including if you have kidney or liver problems. Your dose of MITIGARE® may need

Even medicines that you take for a short period of time, such as antibiotics, can interact with MITIGARE® and cause serious side effects

MITIGARE® is a prescription medication used to prevent gout flares in

It is not known if MITIGARE® is safe and effective for the treatment of:

MITIGARE® is not a pain medicine and it should not be taken to treat pain related to other conditions unless specifically for those conditions.

It is not known if MITIGARE® is safe and effective in children.

Who should not take MITIGARE®?

Do not take MITIGARE® if you have liver and kidney problems and you take certain other medicines. Serious side effects, including death, have been reported in these people even when taken as directed. See "What is the most important information I should know about MITIGARE®?'

What should I tell my healthcare provider before taking MITIGARE®?

Before you take MITIGARE[®], tell your healthcare provider:

· about all of your medical conditions

• if you have kidney or liver problems

• if you are pregnant or plan to become pregnant. It is not known if MITIGARE® can harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.

• if you are breastfeeding or plan to breastfeed. MITIGARE[®] can pass into your breast milk and may harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take MITIGARE®.

Tell your healthcare provider about all the medicines you take, including prescription, over-the-counter medicines, vitamins, or herbal supplements.

 Using MITIGARE[®] with certain other medicines can affect each other causing serious side effects and/or death.

• Do not take MITIGARE® with other medicines unless your healthcare

Know the medicines you take. Keep a list of your medicines with you to show your healthcare provider and pharmacist each time you get a new

Especially tell your healthcare provider if you take:

• medicines that may affect how your liver works (CYP3A4 inhibitors) • cyclosporine (Neoral[®], Gengraf[®], Sandimmune[®])

cholesterol lowering medicines

Ask your healthcare provider or pharmacist if you are not sure if you take any of the medicines listed above. This is not a complete list of all the medicines that can affect MITIGARE[®].

• If you take too much MITIGARE® call your healthcare provider or go to the nearest hospital emergency room right away.

• Do not stop taking MITIGARE® unless your healthcare provider tells you

 If you miss a dose of MITIGARE[®], take it as soon as you remember. If it is almost time for your next dose, skip the missed dose. Take the next

- dose at your regular time. Do not take 2 doses at the same time.
- If you have a gout flare while taking MITIGARE®, tell your healthcare nrovider

What should I avoid while taking MITIGARE®?

• Avoid eating grapefruit or drinking grapefruit juice while taking MITIGARE[®]. It can increase your chances of getting serious side effects.

What are the possible side effects of MITIGARE®?

MITIGARE® can cause serious side effects or death. See "What is the most important information I should know about MITIGARE®?"

Get medical help right away, if you have:

- unusual bleeding or bruising
- increased infections
- weakness or fatigue
- muscle weakness or pain
- numbness or tingling in your fingers or toes
- pale or gray color to your lips, tongue, or palms of your hands
- severe diarrhea or vomiting

The most common side effects of MITIGARE® include abdominal pain, diarrhea, nausea, and vomiting.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all of the possible side effects of MITIGARE[®]. For more information ask your healthcare provider or pharmacist.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store MITIGARE[®]?

- Store MITIGARE® at room temperature between 68° to 77°F (20° to 25°C)
- Keep MITIGARE[®] in a tightly closed container.
- Keep MITIGARE[®] out of the light and away from moisture.

Keep MITIGARE® and all medicines out of the reach of children.

General information about the safe and effective use of MITIGARE[®].

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not take MITIGARE® for a condition for which it was not prescribed. Do not give MITIGARE[®] to other people, even if they have the same symptoms that you have. It may harm them.

This Medication Guide summarizes the most important information about MITIGARE[®]. If you would like more information, talk to your pharmacist or healthcare provider for information about MITIGARE® that is written for health professionals.

For more information, go to www.hikma-americas.com or call 1-800-962-8364.

What are the ingredients in MITIGARE® Capsules?

Active Ingredient: Colchicine

Inactive Ingredients: colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose and sodium starch glycolate. The capsule shell contains gelatin, purified water, titanium dioxide, erythrosine, Brilliant Blue FCF and Quinoline Yellow.

This Medication Guide has been approved by the U.S. Food and Drug Administration.

Mfd. for: Hikma Americas Inc. Memphis, TN 38120

Mfd. by: West-Ward Columbus Inc. Columbus, OH 43228

C50000042/01

8.2 Labor and Delivery

The effect of colchicine on labor and delivery is unknown

8.3 Use in Nursing Mothers

Colchicine is excreted into human milk. Limited information suggests that infants exclusively breastfed receive less than 10 percent of the maternal weight-adjusted dose. While there are no published reports of adverse effects in breast-feeding infants of mothers taking colchicine, colchicine can affect gastrointestinal cell renewal and permeability. Caution should be exercised and breastfeeding infants should be observed for adverse effects when MITIGARE® is administered to a nursing woman

8.4 Pediatric Use

Gout is rare in pediatric patients; the safety and effectiveness of MITIGARE® in pediatric patients has not been evaluated in controlled studies

8.5 Geriatric Use

Because of the increased incidence of decreased renal function in the elderly population, and the higher incidence of other co-morbid conditions in the elderly population requiring the use of other medications, reducing the dosage of colchicine when elderly patients are treated with colchicine should be carefully considered

8.6 Renal Imnairment

No dedicated pharmacokinetic study has been conducted using MITIGARE® in patients with varying degrees of renal impairment Colchicine is known to be excreted in urine in humans and the presence of severe renal impairment has been associated with col chicine toxicity. Urinary clearance of colchicine and its metabolites may be decreased in patients with impaired renal function. Dose reduction or alternatives should be considered for the prophylaxis of gout flares in patients with severe renal impairment. Colchicine is not effectively removed by hemodialysis. Patients who are undergoing hemodialysis should be monitored carefully for colchicine toxicit\

8.7 Hepatic Impairment

No dedicated pharmacokinetic study using MITIGARE® has been conducted in patients with varying degrees of hepatic impairment. Colchicine is known to be metabolized in humans and the presence of severe hepatic impairment has been associated with colchicine toxicity. Hepatic clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic

Dose reduction or alternatives should be considered for the prophylaxis of gout flares in patients with severe hepatic impairment. 9 DRUG ABUSE AND DEPENDENCE

Tolerance, abuse, or dependence from colchicine has not been reported

10 OVERDOSAGE


The dose of colchicine that would induce significant toxicity for an individual is unknown. Fatalities have been reported in patients after ingesting a dose as low as 7 mg over a 4-day period, while other patients have reportedly survived after ingesting more than 60 mg. A review of 150 patients who overdosed on colchicine found that those who ingested less than 0.5 mg/kg survived and tended to have milder adverse reactions, such as gastrointestinal symptoms, whereas those who ingested from 0.5 to 0.8 mg/kg had more severe adverse reactions, including myelosuppression. There was 100% mortality among patients who ingested more than 0.8 mg/kg.

- The first stage of acute colchicine toxicity typically begins within 24 hours of ingestion and includes gastrointestinal symptoms such as abdominal pain, nausea, vomiting, diarrhea, and significant fluid loss, leading to volume depletion. Peripheral leukocytosis may also be seen.
- · Life-threatening complications occur during the second stage, which occurs 24 to 72 hours after drug administration, attributed to multi-organ failure and its associated consequences. Death usually results from respiratory depression and cardio-vascular collapse. If the patient survives, recovery of multi-organ injury may be accompanied by rebound leukocytosis and alopecia starting about 1 week after the initial ingestion.
- Treatment of colchicine overdose should begin with gastric layage and measures to prevent shock. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. Colchicine is not effectively removed by hemodialysis [see Pharmacokinetics (12.3)].

11 DESCRIPTION

Colchicine is an alkaloid obtained from the plant colchicum autumnale

The chemical name for colchicine is (S)-N-(5,6,7,9- tetrahydro-1,2,3,10-tetramethoxy-9 oxobenzol[a]heptalen-7-yl) acetamide. The structural formula is represented be



C22H25NO6

Colchicine consists of pale yellow scales or powder; it darkens on exposure to light. Colchicine is soluble in water, freely soluble in alcohol, and slightly soluble in ether

MITIGARE® (colchicine) capsules are supplied for oral administration. Each capsule contains 0.6 mg Colchicine and the following Protect from light and moisture inactive ingredients: colloidal silicon dioxide, lactose anhydrous, magnesium stearate, microcrystalline cellulose, and sodium starch 17 PATIENT COUNSELING INFORMATION glycolate. The capsule shell contains gelatin, purified water, titanium dioxide, erythrosine, Brilliant Blue FCF and Quinoline Yellow.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Colchicine's effectiveness as a treatment for gout has been postulated to be due to its ability to block neutrophil-mediated inflammatory responses induced by monosodium urate crystals in synovial fluid. Colchicine disrupts the polymerization of β-tubulin into microtubules, thereby preventing the activation, degranulation, and migration of neutrophils to sites of inflammation. Colchicine me complex found in neutrophils and monocytes that mediates interleukin-1 β (IL-1 β) activation also interferes with the inflamm

12.3 Pharmacokinetics

Absorption

In healthy adults, MITIGARE® when given orally reached a mean Cmax of 3 ng/mL in 1.3 h (range 0.7 to 2.5 h) after 0.6 mg single dose administrat

Absolute bioavailability is reported to be approximately 45%

Administration with food has no effect on the rate or extent of colchicine absorption

Colchicine is not effectively removed by hemodialysis.

Distribution

Revised February 2018

Colchicine has a mean apparent volume of distribution in healthy young volunteers of approximately 5 to 8 L/kg. Colchicine binding to serum protein is about 39%, primarily to albumin. Colchicine crosses the placenta and distributes into breast milk [see Pregnancy (8.1) and Nursing Mothers (8.3)].

Metabolism

A published in vitro human liver microsome study showed that about 16% of colchicine is metabolized to 2-0-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively) by CYP3A4. Glucuronidation is also believed to be a metabolic pathway for colchicine

Excretion

In a published study in healthy volunteers, 40 to 65% of the total absorbed dose of colchicine (1 mg administered orally) was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also believed to play a role in colchicine elimination. Colchicine is a substrate of P-gp and P-gp efflux is postulated to play an important role in colchicine disposition. Elimination half-life in humans was found to be 31 h (range 21.7 to 49.9 h).

Special Populations

S There is no difference between men and women in the pharmacokinetic disposition of colchicine

Pediatric Patients: Pharmacokinetics of colchicine was not evaluated in pediatric patients

Elderly: Pharmacokinetics of colchicine have not been determined in elderly patients. A published report described the pharmacokinetics of 1 mg oral colchicine tablet in four elderly women compared to six young healthy males. The mean age of the four elderly women was 83 years (range 75 to 93), mean weight was 47 kg (38 to 61 kg) and mean creatinine clearance was 46 mL/min (range 25 to 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males. It is possible that the higher exposure in the elderly subjects was due to decreased renal function.

Renal impairment: Pharmacokinetics of colchicine in patients with mild and moderate renal impairment is not known. A published report described the disposition of colchicine (1 mg) in young adult men and women patients who had end-stage renal disease equiring dialysis compared to patients with normal renal function. Patients with end-stage renal disease had 75% lower colchicine clearance (0.17 vs. 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hrs vs. 4.4 hrs) as compared to subjects with normal renal function [see Renal Impairment (8.6)]

Henatic impairment: Published reports on the pharmacokinetics of intravenous colchicine in patients with severe chronic liver disease, as well as those with alcoholic or primary biliary cirrhosis, and normal renal function suggest wide inter-patient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with primary biliary cirrhosis, no consistent trends were noted [see Hepatic Impairmen (8.7)]. No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).

Drug Interactions

Pharmacokinetic studies evaluating changes in systemic levels of colchicine when co-administered with CYP3A4 inhibitors in healthy volunteers have been conducted with MITIGARE[®]. While voriconazole 200 mg BID for 5 days (considered a strong CYP3A4 inhibitor) and cimetidine 800 mg BID for 5 days (considered a weak CYP3A4 inhibitor) did not cause any changes in colchicine systemic levels fuccinaziole 200 mg DD for 4 days with a 400 mg loading dose (considered a moderate CVP3A4 inhibitor) increased colchicine AUC by 40%. As voriconazole, cimetidine, and fluconazole are known as CYP3A4 inhibitors that do not inhibit P-gp, these studies show that CYP3A4 inhibition by itself may not lead to clinically significant increases in colchicine systemic levels in humans, and P-gp inhibition in addition to CYP3A4 inhibition may be necessary for clinically meaningful interactions of colchicine. However, based on published case reports that indicate the presence of colchicine toxicity when colchicine is co-administered with strong to moderate CYP3A4 inhibitors such as clarithromycin, erythromycin, grapefruit juice, etc., as well as the 40% increase in systemic levels of colchicine observed with concomitantly administered fluconazole (a moderate CYP3A4 inhibitor that is not known to inhibit P-gp) in a drug-drug interaction study, the drug-drug interaction potential of colchicine with strong or moderate CYP3A4 inhibitors that do not inhibit P-op cannot be ruled out completely

Co-administration of MITIGARE® with propatenone (a P-gp inhibitor) at 225 mg BID for 5 days, in a pharmacokinetic study in healthy volunteers, did not cause any changes in systemic levels of colchicine. This indicates that propatenone can be administered with MITIGARE® without any dose adjustment. However, these results should not be extrapolated to other P-gp inhibitors as colchicine is known to be a substrate for P-gp and case reports of colchicine toxicity associated with the co-administration of P-gp inhibitors such as cyclosporine have been published.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Carcinogenesis Carcinogenicity studies of colchicine have not been conducted. Due to the potential for colchicine to produce aneuploid cells (cells with an unequal number of chromosomes), colchicine presents a theoretical increased risk of malignancy

Mutanenesis

M.W. 399.44

Published studies demonstrated that colchicine was negative for mutagenicity in the bacterial reverse mutation assay. However, in vitro chromosomal aberration assays demonstrated the formation of micronuclei following colchicine treatment. Because published studies demonstrated that colchicine induces aneuploidy through the process of mitotic nondisjunction without structural DNA changes, colchicine is not considered clastogenic, although micronuclei are formed.

Impairment of Fertility

There were no studies of the effects of MITIGARE® on fertility. However, published nonclinical studies have demonstrated that colchicine-induced disruption of microtubule formation affects meiosis and mitosis. Published reproductive studies with colchicine reported abnormal sperm morphology and reduced sperm counts in males, and interference with sperm penetration, second meiotic division, and normal cleavage in females.

Case reports and epidemiology studies in human male subjects on colchicine therapy indicate that infertility from colchicine is rare A case report indicated that azoospermia was reversed when therapy was stopped. Case reports and epidemiology studies in female subjects on colchicine therapy have not established a clear relationship between colchicine use and female infertility.

14 CLINICAL STUDIES

The evidence for the efficacy of colchicine in patients with chronic gout is derived from the published literature. Two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of gout flares in patients with gout initiating treatment with urate lowering therapy. In both trials, treatment with colchicine decreased the frequency of gout flares

16 HOW SUPPLIED/STORAGE AND HANDLING

16.1 How Supplied MITIGARE® (colchicine) capsules, 0.6 mg are No. 4 Dark Blue/Light Blue Hard Gelatin Capsules printed "West-ward 118" in white ink

NDC 59467-318-30: Bottle of 30 Capsules

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

schedule. However, if a dose is skipped, the patient should not double the next dose

colchicine. MITIGARE® should be kept out of the reach of children

NDC 59467-318-01: Bottle of 100 Cansules

NDC 59467-318-10: Bottle of 1000 Capsules

16.2 Storage

Dosing Instructions

Fatal Overdose

Blood Dyscrasia

Drug and Food Interactions

Neuromuscular Toxicity

evaluation immediately.

Hikma Americas Inc. Memphis, TN 38120

Columbus, OH 43228

C50000042/01

West-Ward Columbus Inc.

Mfd. for:

Mfd by

be consumed during treatment with MITIGARE®

GARF®

If a dose of MITIGARE® is missed, advise the patient to take the dose as soon as possible and then return to the normal dosing

Advise the patient that fatal overdoses, both accidental and intentional, have been reported in adults and children who have incested

Advise patients that bone marrow depression with agranulocytosis, aplastic anemia, and thrombocytopenia may occur with MITI-

Advise patients that many drugs or other substances may interact with MITIGARE® and some interactions could be fatal. Therefore patients should report to their healthcare provider all of the current medications they are taking, and check with their healthcare provider before starting any new medications, including short-term medications such as antibiotics. Patients should also be advised to report the use of non-prescription medication or herbal products. Grapefruit and grapefruit juice may also interact and should not

Advise patients that muscle pain or weakness, tingling or numbness in fingers or toes may occur with MITIGARE® alone or when it is used with certain other drugs. Patients developing any of these signs or symptoms must discontinue MITIGARE® and seek medical

